⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Anwita Biosciences, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Anwita Biosciences, Inc.
↗San Carlos, USA
Anwita Biosciences is a clinical-stage biopharmaceutical company headquartered in the San Francisco Bay Area. The company focuses on the development of innovative protein-based therapeutics, specifically antibodies and bifunctional fusion proteins, to treat cancer and autoimmune diseases. Their platform aims to precisely reprogram immunity and tumor biology to deliver durable patient benefits.
The company's lead clinical candidate, AWT020, is a bifunctional fusion protein that combines an anti-PD-1 nanobody with a potency-optimized IL-2 mutein. This candidate has received FDA Orphan Drug Designation for the treatment of Thymic Epithelial Tumors (TETs) and is currently being evaluated in Phase 1 clinical trials for various advanced solid tumors.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2017
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$10M
Investors:Junshi Biosciences
PIPELINE
Stage:Phase 1
Lead Drug Stage:Phase 1
Modalities:Fusion proteins, Antibodies, Nanobody
Active Trials:2
Trial Phases:Phase 1: 2
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Junshi Biosciences (Licensing and investment collaboration for AWT008 in Greater China)
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Ziyang Zhong - CEO
Eugene Liu - CMO
LINKS
Website:anwitabio.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Anwita Biosciences, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.